Immunosin tab.500mg in strips in pack No. 10×5

NameImmunozin tabl. The main active ingredient Inosine pranobex Release form tablets Dosage 500 mg It is used both for monotherapy and in complex treatment with antibiotics, antiviral and other etiotropic agents. With continuous treatment for more than 14 days, it is necessary to monitor the level of uric acid in the blood serum and urine, with treatment for more than 21 days, it is advisable to monthly monitor the function of the liver and kidneys (transaminase activity, creatinine level), the composition of peripheral blood. Immunosin® should not be prescribed to patients with hyperuricemia due to the possibility of an increase in serum and urine uric acid levels. If it is necessary to use the drug in this category of patients, the content of uric acid in the body should be regularly monitored. Patients with a significant increase in uric acid levels are advised to simultaneously take drugs that lower its level. Patients with acute liver failure require a dose reduction of Immunosin®, tk. the process of metabolism of inosine pranobex occurs in the liver. In the cases listed above, before taking Immunozin®, a consultation with a doctor is required. Children. It is used in children over 1 year old. Elderly patients. In elderly patients, dose adjustment is not required, the drug is used as in adults. It should be borne in mind that in the elderly, an increase in the concentration of uric acid in the blood serum and urine occurs more often than in middle-aged patients. Pharmacological properties Immunosin® is an immunostimulating drug with antiviral activity. The active substance inosine pranobex (a complex of inosine and a salt of 4-acetamidobenzoic acid with 1-dimethylamino-2-propanol in a molar ratio of 1:3) exhibits a direct antiviral and immunomodulatory effect. The antiviral effect is due to binding to the ribosomes of virus-affected cells, which slows down the synthesis of viral mRNA (impaired transcription and translation) and leads to inhibition of the replication of RNA and DNA genomic viruses. Indications for use Infections of the skin and mucous membranes caused by herpes simplex viruses type I or type II (herpes simplex), as well as diseases caused by the Varicella zoster virus (chicken pox and shingles). Papillomavirus infection of the anogenital region, genital warts, as an adjunct to the therapy of chemical, CO2-laser, cryo and electrocoagulation destruction. Subacute sclerosing panencephalitis. Immunodeficiency states caused by viral infections in patients with a weakened immune system. Dosage and administration Immunozin® is taken orally after meals at regular intervals 3-4 times a day with a small amount of water. If necessary, the tablet can be chewed. In children under 6 years of age, the Immunosin® tablet must be crushed and / or dissolved in a small amount of liquid before use, due to an increased risk of aspiration. The duration of treatment is determined by the nature, severity of the disease, the frequency of relapses, etc. The course of treatment averages 5-14 days. After a 7-10-day break, if necessary, the course can be repeated. Treatment with interruptions and maintenance doses can last from 1 to 6 months. Recommended doses and regimens for the use of the drug Labial herpes, chickenpox and herpes zoster: adults – 2 tablets 3-4 times a day; children – a daily dose of 50 mg / kg in 3-4 doses for 10-14 days (until symptoms disappear). Genital herpes: in the acute period – 2 tablets 3 times a day for 5-6 days; during remission maintenance dose – 2 tablets (1000 mg) 1 time per day – up to 6 months. Papillomavirus infection of the anogenital region, genital warts, as an adjunct to the therapy of chemical, CO2 laser, cryo and electrocoagulation destruction: 2 tablets 3 times a day, course of treatment – 14-28 days; when combined with cryotherapy or CO2 laser therapy – 2 tablets 3 times a day for 5 days, 3 courses with an interval of 1 month. Subacute sclerosing panencephalitis: daily dose at the rate of 50-100 mg / kg for 6 doses (every 4 hours) for 8-10 days; after an 8-day break with a mild course, an additional 1-3 courses, with a severe course – up to 9 courses. Patients with weakened immunity (in complex treatment): adults – 2 tablets 3-4 times a day, course of treatment – from 2 weeks to 3 months; children – a daily dose of 50 mg / kg in 3-4 doses for 21 days (or 3 courses of 7-10 days with the same breaks). When correcting immunodeficiency states, the duration of the course of treatment can be from 3 to 9 weeks. Use during pregnancy and lactation IMMUNOSIN® is contraindicated during pregnancy and lactation (breastfeeding), because. its safety in this category of patients has not been established. Interaction with other drugs With the simultaneous use of immunosuppressants may reduce the effectiveness of Immunosin®. Xanthine oxidase inhibitors and uricosuric agents (including diuretics) may contribute to the risk of elevated serum uric acid levels in patients taking Immunosin®. The combined use of inosine pranobex with zidovudine leads to an increase in the level of the latter in the blood and an increase in its half-life. This allows you to prescribe lower doses of zidovudine and increase the intervals between doses when used together with inosine pranobex. If the patient is taking other medications, the doctor should be consulted. Contraindications gout; urolithiasis disease; severe renal failure III degree; arrhythmia; children’s age up to 1 year; pregnancy; lactation period (breastfeeding); hypersensitivity to the components of the finished dosage form. Composition Each tablet contains 500 mg of metisoprinol (inosine pranobex) as an active substance. Excipients: povidone, magnesium stearate, corn starch. Overdose No data on overdose of inosine pranobex have been identified. In case of overdose, gastric lavage and symptomatic therapy are recommended. Side effect Determination of the frequency of adverse reactions: often (? 1% and <10%), sometimes (? 0.1% and <1%). Immunosin® is well tolerated even with prolonged use. Most often, a short-term slight increase in the concentration of uric acid in the blood serum and urine, caused by the metabolism of inosine, is noted. From the digestive system: often - nausea, vomiting, epigastric pain, a temporary increase in the activity of transaminases and alkaline phosphatase. Dermatological reactions: often - itching. From the side of the central nervous system: often - headache, dizziness, weakness; sometimes - drowsiness, insomnia. From the urinary system: sometimes - polyuria. From the musculoskeletal system: often - joint pain. From the side of metabolism: often - exacerbation of gout, an increase in the content of uric acid in the blood plasma. If the above adverse reactions occur, discontinue use and consult a doctor as soon as possible. Storage conditionsStore at a temperature not exceeding 25°C. Keep out of the reach of children. Buy Immunozin tab. 500mg in strips in pack No. 10x5 Price for Immunozin tab. 500mg in strips in pack No. 10x5